1.646.889.1200|info@lifescipublicrelations.com

Orchard Gains GSK’S Rare Disease Gene Therapy Portfolio

//Orchard Gains GSK’S Rare Disease Gene Therapy Portfolio

Orchard Gains GSK’S Rare Disease Gene Therapy Portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.).

By | 2018-04-27T12:47:01-04:00 April 12th, 2018|News|Comments Off on Orchard Gains GSK’S Rare Disease Gene Therapy Portfolio

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.